Last Update 26 Jun 26
Fair value Decreased 4.15%HTFL: Beat And Raise Performance Will Face Sector Pressure Ahead
HeartFlow's analyst price target has moved to $37.00, with analysts citing the recent Q1 sales beat, raised full year sales guidance, and sector multiple shifts as key drivers of the updated fair value inputs.
Analyst Commentary
Analysts covering HeartFlow are updating their views around the new US$37.00 price target, focusing on how recent results and sector moves affect valuation, execution risk, and future growth potential.
Bullish Takeaways
- Bullish analysts highlight the US$3m Q1 sales beat as evidence that HeartFlow is currently executing ahead of the assumptions embedded in prior fair value work.
- Raised full year sales guidance by US$10m is seen as a sign that management has increased confidence in the revenue pipeline, particularly as Plaque is tracking ahead of prior expectations.
- Strength in FFRCT performance is viewed as supportive of HeartFlow’s core business, which bullish analysts see as important for underpinning the updated US$37.00 valuation framework.
- Some bullish analysts point to management’s view that guidance is de risked, arguing this could lower perceived execution risk around the company’s growth targets.
Bearish Takeaways
- Bearish analysts, despite acknowledging the beat and raise, cite sector multiple pressure as a key reason to temper valuation assumptions at the new US$37.00 target.
- The reduction in one firm’s target from US$43.00 to US$37.00, even alongside higher revenue estimates, reflects caution that peer group compression may limit multiple expansion for HeartFlow.
- There is concern that current guidance, while raised, still relies on continued strong momentum in Plaque and FFRCT, which introduces execution risk if adoption trends slow.
- Some cautious views focus on the broader comp group, suggesting that even solid company level performance may not fully offset a weaker sector backdrop in valuation work.
What’s in the News for HeartFlow
- HeartFlow is being compared with NovoCure in recent coverage that weighs both stocks as potential healthcare investments in 2026, highlighting HeartFlow’s focus on non invasive AI based coronary artery disease diagnosis versus NovoCure’s electric field cancer therapies. Source: HeartFlow vs. NovoCure article.
- The comparison piece notes that both HeartFlow and NovoCure are growing revenue but are still unprofitable and face regulatory and commercial risks, giving investors a clearer view of the risk profile around HeartFlow’s business model. Source: HeartFlow vs. NovoCure article.
- Analysts in the same article describe NovoCure as having higher projected revenue in 2026 and a more conservative valuation. This is framed as making NovoCure a more attractive long term investment relative to HeartFlow. Source: HeartFlow vs. NovoCure article.
- HeartFlow raised 2026 total revenue guidance to a range of US$228m to US$232m, compared with prior guidance of US$218m to US$222m, with the company describing the implied year over year growth ranges as approximately 29% to 32% versus approximately 24% to 26%. Source: Company guidance update.
Valuation Changes for HeartFlow
- Fair Value: updated from $38.60 to $37.00, reflecting a modest reduction in the implied target level.
- Discount Rate: adjusted slightly lower from 8.25% to 8.03%, reflecting a small change in the risk assumptions used in HeartFlow’s valuation model.
- Revenue Growth: revised from 23.50% to 24.45%, indicating a small uplift in expected top line growth for HeartFlow.
- Net Profit Margin: moved from 6.93% to 6.69%, reflecting a slight reduction in the long run profitability assumption.
- Future P/E: reduced from 241.78x to 198.57x, indicating a meaningful reset in the valuation multiple applied to HeartFlow’s projected earnings.
3 viewsusers have viewed this narrative update
Catalysts
About HeartFlow
HeartFlow provides an AI based software platform that supports detection, diagnosis, management and treatment planning for coronary artery disease using cardiac CT imaging.
What are the underlying business or industry changes driving this perspective?
- Growing use of coronary CT angiography as a front line test for chest pain, supported by guidelines and higher reimbursement, increases the pool of scans that can run through HeartFlow's platform and can support revenue growth as case volumes scale.
- The transition of HeartFlow Plaque Analysis to a Category 1 CPT code in 2026, with defined Medicare payment rates in both clinic and hospital settings and commercial coverage already at 57% of U.S. lives, sets up a path for more routine clinical use that can add a new revenue stream and support gross margin mix over time.
- Expanding the sales footprint focused on referring cardiologists, with the TAM team targeted to double by year end 2025, is aimed at deeper referral activation across the existing installed base and can support continued case growth and operating leverage as fixed commercial costs are spread over higher revenue.
- The launch of PCI Navigator into interventional cardiology, backed by registry and study data and integrated with existing HeartFlow tools, broadens the platform's role across the full CAD care pathway and can increase revenue per account while supporting account retention and potentially higher net margins.
- Large scale clinical datasets such as the DECIDE registry and plaque staging data from FISH&CHIPS, together with an AI platform trained on over 110 million images, help reinforce physician and payer confidence in image based CAD management and can support sustained adoption that benefits long term revenue visibility and earnings potential.
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming HeartFlow's revenue will grow by 24.5% annually over the next 3 years.
- Analysts are not forecasting that HeartFlow will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate HeartFlow's profit margin will increase from -58.4% to the average US Healthcare Services industry of 6.7% in 3 years.
- If HeartFlow's profit margin were to converge on the industry average, you could expect earnings to reach $24.7 million (and earnings per share of $0.23) by about June 2029, up from -$111.8 million today.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 199.8x on those 2029 earnings, up from -27.0x today. This future PE is greater than the current PE for the US Healthcare Services industry at 28.1x.
- Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 8.03%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?
- If coronary CT angiography adoption slows versus historical low 20% growth in the underlying category that management referenced, HeartFlow could see fewer new scans flowing into its platform, which would directly affect revenue growth and the ability to scale fixed costs.
- HeartFlow is emphasizing Plaque Analysis as the next wave of growth, but management does not expect material adoption until coverage exceeds 70% of U.S. lives and physician education catches up. Any delay in coverage expansion or slower than expected clinical uptake could reduce the long term contribution to revenue and gross margin mix.
- The company is rapidly expanding its territory account manager sales force and investing heavily in R&D and clinical studies. If these investments do not translate into sustained case growth, operating leverage could stall and the company may experience continued operating losses and pressure on earnings.
- HeartFlow is positioning PCI Navigator and the broader end to end platform as critical tools across the full coronary artery disease care pathway. If interventional cardiologists or hospitals prefer established invasive workflows or competing tools, adoption could be limited and constrain revenue per account and future margin expansion.
- Management states that the company is well capitalized to fund operations through profitability and is targeting cash flow profitability within 3 years of the IPO. If case volumes, pricing, or reimbursement trends fall short of what is needed to support that path, the company could face extended periods of net losses and may eventually need additional capital.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of $37.0 for HeartFlow based on their expectations of its future earnings growth, profit margins and other risk factors.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $369.0 million, earnings will come to $24.7 million, and it would be trading on a PE ratio of 199.8x, assuming you use a discount rate of 8.0%.
- Given the current share price of $34.98, the analyst price target of $37.0 is 5.5% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on HeartFlow?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Read more narratives
There are no other narratives for this company.
View all narratives